Important Triad in Cardiovascular Medicine
2003; Lippincott Williams & Wilkins; Volume: 107; Issue: 11 Linguagem: Romeno
10.1161/01.cir.0000055653.52489.e9
ISSN1524-4539
Autores Tópico(s)Antiplatelet Therapy and Cardiovascular Diseases
ResumoHomeCirculationVol. 107, No. 11Important Triad in Cardiovascular Medicine Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBImportant Triad in Cardiovascular MedicineDiabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Receptor Blockade A. Michael Lincoff, MD A. Michael LincoffA. Michael Lincoff From the Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio. Originally published25 Mar 2003https://doi.org/10.1161/01.CIR.0000055653.52489.E9Circulation. 2003;107:1556–1559Diabetes mellitus is a potent risk factor for greater prevalence, complexity, and complications of cardiovascular disease, and diabetics thus constitute a sizable proportion of patients for whom coronary revascularization is required. However, both percutaneous and surgical revascularization techniques are associated with particular challenges in this population. Diabetics typically have an increased likelihood of restenosis and repeat revascularization procedures after stenting compared with their non-diabetic counterparts.1 Trends toward higher death rates in diabetics have also been observed over 1 year or longer after stenting,1–4 and patients with diabetes thus remain one of the few groups for whom percutaneous coronary intervention (PCI) does not yet provide survival benefit commensurate with that of coronary artery bypass surgery.5–7 Diabetes mellitus is also a predictor of elevated mortality risk and accelerated disease progression after surgical revascularization.5,8,9The processes leading to adverse prognosis after revascularization in diabetics are likely multifactorial and relate to widespread atheroma, small vessel vasculopathy, impaired collateral formation, exuberant neointimal hyperplasia, and adverse remodeling.10,11 There is also evidence that hypercoagulability contributes to accelerated atherosclerosis and exaggerated injury response after revascularization in diabetics.11–13 Diabetes is associated with increased levels of circulating fibrinogen, thrombin, and factor VII, and with diminished plasma fibrinolytic and antithrombin III activity. Moreover, platelets in diabetic patients are increased in size, are more frequently activated, and exhibit greater adhesiveness, thromboxane synthesis, glycoprotein (GP) IIb/IIIa expression, and mitogenic activity.Glycoprotein IIb/IIIa Inhibitors and DiabetesAdjunctive antiplatelet therapy with GP IIb/IIIa blockade reduces the incidence of acute ischemic events by as much as 35% to 50% among the broad population of patients undergoing elective or urgent PCI,14 and evidence supporting long-term suppression of mortality with at least one of these inhibitors, abciximab, has been accrued as well.3,15,16 The benefits of GP IIb/IIIa inhibitors in this setting seem to be complementary to those of stenting, with the latter influencing endpoints related to mechanical disruption of atherosclerotic plaque or restenosis at the interventional site but having little impact on mortality or myocardial infarction. Given that the pathogenesis of cardiovascular complications of diabetes may be due at least in part to heightened coagulation and platelet activity, there are rationale to believe that GP IIb/IIIa blockade may have enhanced efficacy among patients with diabetes undergoing PCI. Unfortunately, published analyses of the diabetic patient subsets from the various GP IIb/IIIa trials have assessed different agents and forms of percutaneous revascularization (stent versus non-stent) and used different endpoints and durations of follow-up, thus contributing to a perception of inconsistency within the body of evidence for benefit of GP IIb/IIIa blockade among diabetic patients. A more systematic approach to the clinical trial data set, however, clarifies many of these apparent discrepancies.Different "ischemic" endpoints do not necessarily relate to the same pathophysiological processes, and composite endpoints incorporating diverse events may therefore fail to appropriately reflect therapeutic efficacy. The GP IIb/IIIa inhibitor trials have typically used a composite of death, myocardial infarction, or urgent revascularization by 30 days as the primary endpoint, events which occur as a result of thrombosis, embolization, or mechanical plaque disruption during PCI. Over the follow-up period to 6 months or 1 year, however, revascularization events due principally to restenosis, a process distinct from acute thrombosis or vascular dissection, become dominant. For example, among patients in the placebo group of one recent trial of eptifibatide during stenting, myocardial infarction rates increased by only an absolute 0.7% between 30 days and 6 months, whereas target vessel revascularization (TVR) rates increased by an absolute 7.1% during that same interval.17 Thus, durability of benefit after 30 days with regard to acute ischemic events is best assessed using an endpoint confined to death or myocardial infarction, whereas an independent influence on restenosis would be reflected by separate determination of TVR rates. Finally, multiple processes contribute to long-term mortality, typically evaluated at 1 year or more, with the caveat that individual interventional trials seldom have statistical power to detect less than a major mortality benefit.Of the trials of GP IIb/IIIa blockade during PCI, 5 have reported detailed outcome for diabetic versus non-diabetic patients. The Evaluation of c7E3 for Prevention of Ischemic Complications (EPIC),18,19 Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade (EPILOG),20,21 and Evaluation of Platelet Inhibition in STENTing (EPISTENT)3,22–24 trials compared abciximab to placebo among patients undergoing non-stent interventions (EPIC, EPILOG, and 1 arm of EPISTENT) or stenting (2 arms of EPISTENT). The Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT)2,17,25,26 trial compared eptifibatide to placebo and the do Tirofiban And ReoPro Give similar Efficacy Trial (TARGET)27 compared tirofiban to abciximab during stenting. The proportions of patients with diabetes in these trials ranged from 20% to 24%, with inconsistent differentiation within the databases among those treated with insulin, oral agents, or dietary therapy. The total data set for the 4 placebo-controlled trials consists of 2099 diabetic and 7252 non-diabetic patients, with an additional 1117 and 3692 patients with and without diabetes, respectively, in the active-control TARGET trial.Figure 1 illustrates the treatment effect of GP IIb/IIIa blockade with abciximab or eptifibatide relative to placebo on the acute 30-day endpoint of death, myocardial infarction, or urgent revascularization after PCI in diabetic and non-diabetic patients. The magnitude of risk reduction with GP IIb/IIIa inhibition was similar for patients with or without diabetes, with no evidence of enhanced or diminished benefit in either patient subgroup. Moreover, event rates did not consistently or significantly vary between those with or without diabetes, a finding concordant with other contemporary studies showing similar risk for short-term ischemic complications after PCI in diabetic and non-diabetic patients. In TARGET, the advantage of abciximab over tirofiban with regard to the primary 30-day endpoint was observed for patients with (14% relative risk reduction) and without (22% relative risk reduction) diabetes. Durability of the treatment effect of abciximab or eptifibatide on the endpoint of death or myocardial infarction over 6 months is also depicted in Figure 1, with comparable risk reductions observed in diabetic and non-diabetic patients. Download figureDownload PowerPointFigure 1. Odds ratio and 95% confidence intervals for 30-day (left) and 6-month (right) ischemic endpoints among diabetic and non-diabetic patients in placebo-controlled trials of abciximab (EPIC, EPILOG, and EPISTENT) or eptifibatide (ESPRIT). MI indicates myocardial infarction.*Stent arms (placebo versus abciximab) only in EPISTENT.Outcome at 6 months with regard to TVR, the clinical surrogate for restenosis, is shown in Figure 2. The baseline (placebo group) risk for TVR was higher among diabetics than non-diabetics in all trials except EPILOG, in keeping with previous studies demonstrating an increased likelihood of restenosis among diabetic patients. The lower TVR rate among diabetics in the placebo group of EPILOG21 was likely a chance spurious finding. In contrast to the consistent influence of GP IIb/IIIa inhibition on acute ischemic events (Figure 1), the effect of these agents on 6-month rates of TVR varied considerably among trials and between diabetic or non-diabetic subgroups (Figure 2). After balloon angioplasty or atherectomy in EPIC, a benefit of abciximab on TVR was apparent in patients without diabetes, but not in those with diabetes. In EPILOG, neither diabetic nor non-diabetic patients experienced a reduction in TVR rates with abciximab. Conversely, in EPISTENT, abciximab therapy was associated with a significant 50% decrease in TVR rates after stenting among diabetics but not among non-diabetics, a finding confirmed by improved angiographic indices of restenosis in the angiographic substudy of that trial.23,24 In the ESPRIT trial, there was no effect of eptifibatide on TVR after stenting in either diabetic or non-diabetic patients. Download figureDownload PowerPointFigure 2. Odds ratio and 95% confidence intervals for 6-month TVR endpoint among diabetic and non-diabetic patients in placebo-controlled trials of abciximab (EPIC, EPILOG, and EPISTENT) or eptifibatide (ESPRIT). *Stent arms (placebo versus abciximab) only in EPISTENT.It thus remains unclear whether GP IIb/IIIa blockade diminishes the likelihood of restenosis in any patient subgroup or with any type of interventional procedure. It is tempting to hypothesize on the basis of the EPISTENT results that abciximab may exert a selective effect on neointimal hyperplasia (the predominant mechanism of restenosis after stenting) in the patient subgroup known to be at high risk for this process (diabetics); support for this concept could also be derived from the subgroup of 53 patients with diabetes in the Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up (ADMIRAL) trial,28 in whom randomization to abciximab rather than placebo during primary stenting for acute myocardial infarction was associated with a significant decrease in 6-month rates of TVR (12.5 versus 0%, P=0.049). The lack of influence of eptifibatide on TVR among diabetics in the ESPRIT trial, however, argues against an important effect of GP IIb/IIIa blockade on restenosis, unless such an effect is also mediated by blockade of the αvβ3 or αMβ2 receptors. Such non-specific binding is unique to abciximab among the GP IIb/IIIa inhibitors,29,30 but fails to explain why TVR rates were not improved by abciximab relative to tirofiban (a highly-selective GP IIb/IIIa inhibitor) among diabetics in TARGET (10.8% with abciximab versus 8.8% with tirofiban, P=0.257).The potential for GP IIb/IIIa blockade to diminish mortality was first demonstrated by the results of the EPISTENT trial, in which a significant 60% reduction in 1-year mortality was observed with abciximab among stented patients.3 The finding of long-term mortality benefit with abciximab during PCI was corroborated by pooled analyses of the different abciximab interventional trials,15,16 wherein death rates were significantly diminished by 20% to 30% over 3 years or longer. By multivariate analysis, diabetes was shown to be an independent predictor of mortality and of the magnitude of survival advantage imparted by abciximab therapy,31 with mortality reduction particularly apparent among diabetic patients treated with stents.32 The body of evidence supporting mortality benefit with eptifibatide is substantially smaller than that for abciximab. Nevertheless, both the EPISTENT3 and ESPRIT2 trials suggested that mortality reduction with abciximab or eptifibatide after stenting is enhanced in diabetic relative to non-diabetic patients (Figure 3), a benefit which strikingly seems to neutralize the higher mortality risk after PCI among diabetics. Death rates in diabetic patients at 1 year were not different between tirofiban and abciximab groups in TARGET (2.1 versus 2.9%, respectively), although the statistical power of this non-inferiority comparison was quite limited. Download figureDownload PowerPointFigure 3. One-year mortality rates among diabetic and non-diabetic patients in EPISTENT and ESPRIT placebo-controlled trials. *Stent arms (placebo versus abciximab) only in EPISTENT.A meta-analysis of over 29 000 patients enrolled in 6 large-scale trials of empiric GP IIb/IIIa blockade for non-ST-elevation acute coronary syndromes further supports the linkage between diabetes and survival advantage with these agents.33 Among 6458 diabetic patients, treatment with GP IIb/IIIa inhibitors was associated with a significant reduction in 30-day mortality (6.2 versus 4.6%, P=0.007), a benefit which was particularly marked in the subset of patients who underwent PCI during the index hospitalization (4.0 versus 1.2%, P=0.002). In contrast, no reduction in death rates was observed with GP IIb/IIIa blockade among non-diabetic patients.SummaryThe randomized trial data set provides consistent evidence for a marked reduction in acute ischemic events by GP IIb/IIIa blockade during PCI, the magnitude of which is similar in diabetic and non-diabetic patients. Whether there are quantitative differences in this treatment effect among the 3 GP IIb/IIIa inhibitors continues to be a point of controversy. The impact of GP IIb/IIIa blockade on "clinical restenosis" among diabetic or non-diabetic patients remains unknown. With the introduction into clinical practice of drug-eluting stents, restenosis may no longer be a major limitation of percutaneous revascularization in patients with diabetes. What emerges then as the most compelling argument for GP IIb/IIIa inhibition during PCI in diabetics is the distinctive late mortality advantage; in this regard, abciximab remains the reference standard, with a body of long-term mortality data unmatched by other agents. GP IIb/IIIa blockade in combination with drug-eluting stents has the potential for true complementarity to optimize outcome after revascularization in this important high-risk group of patients.Dr Lincoff has received research funding from Eli Lilly, Centocor, and COR-Millennium Pharmaceuticals.FootnotesCorrespondence to A. Michael Lincoff, MD, Associate Professor of Medicine, Department of Cardiovascular Medicine, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail [email protected] References 1 Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998; 32: 1866–1873.CrossrefMedlineGoogle Scholar2 Labinaz M, Madan M, O'Shea JC, et al. Comparison of one-year outcomes following coronary artery stenting in diabetic versus non-diabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin therapy [ESPRIT] trial). Am J Cardiol. 2002; 90: 585–590.CrossrefMedlineGoogle Scholar3 Topol EJ, Mark DB, Lincoff AM, et al. Enhanced survival with platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: one year outcomes and health care economic implications from a multicenter, randomized trial. Lancet. 1999; 354: 2019–2024.CrossrefMedlineGoogle Scholar4 Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998; 32: 584–589.CrossrefMedlineGoogle Scholar5 Bypass Angioplasty Revascularization (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996; 335: 217–225.CrossrefMedlineGoogle Scholar6 King SB, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol. 2000; 35: 1116–1121.CrossrefMedlineGoogle Scholar7 Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation. 2001; 104: 533–538.CrossrefMedlineGoogle Scholar8 Risum O, Abdelnoor M, Svennevig JL, et al. Diabetes mellitus and morbidity and mortality risks after coronary artery bypass surgery. Scan J Thorac Cardiovasc Surg. 1996; 30: 71–75.CrossrefMedlineGoogle Scholar9 Herlitz J, Wognsen GB, Emanuelsson H, et al. Mortality and morbidity in diabetic and nondiabetic patients during a 2 year period after coronary artery bypass grafting. Diabet Care. 1996; 19: 698–703.CrossrefMedlineGoogle Scholar10 Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996; 27: 528–535.CrossrefMedlineGoogle Scholar11 Hammoud T, Tanguay J-F, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol. 2000; 36: 355–365.CrossrefMedlineGoogle Scholar12 Jokl R, Colwell JA. Arterial thrombosis and atherosclerosis in diabetes. Diabet Rev. 1997; 5: 316–330.Google Scholar13 Tschoepe D. The activated megakaryocyte-platelet system in vascular disease: focus on diabetes. Semin Thromb Hemost. 1995; 21: 152–160.CrossrefMedlineGoogle Scholar14 Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa blockade in coronary artery disease. J Am Coll Cardiol. 2000; 35: 1103–1115.CrossrefMedlineGoogle Scholar15 Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002; 113: 1–6.CrossrefMedlineGoogle Scholar16 Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001; 37: 2059–2065.CrossrefMedlineGoogle Scholar17 O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT Trial: a randomized controlled trial. JAMA. 2001; 285: 2468–2473.CrossrefMedlineGoogle Scholar18 EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994; 330: 956–961.CrossrefMedlineGoogle Scholar19 Topol EJ, Califf RM, Weisman HS, et al. Reduction of clinical restenosis following coronary intervention with early administration of platelet IIb/IIIa integrin blocking antibody. Lancet. 1994; 343: 881–886.CrossrefMedlineGoogle Scholar20 EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336: 1689–1696.CrossrefMedlineGoogle Scholar21 Kleiman NS, Lincoff AM, Kereiakes DJ, et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence of a complex interaction in a multicenter trial. Circulation. 1998; 97: 1912–1920.CrossrefMedlineGoogle Scholar22 EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998; 352: 87–92.CrossrefMedlineGoogle Scholar23 Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999; 341: 319–327.CrossrefMedlineGoogle Scholar24 Marso S, Lincoff A, Ellis S, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Circulation. 1999; 100: 2477–2484.CrossrefMedlineGoogle Scholar25 ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000; 356: 2037–2044.CrossrefMedlineGoogle Scholar26 O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2002; 287: 618–621.CrossrefMedlineGoogle Scholar27 Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Eng J Med. 2001; 344: 1888–1894.CrossrefMedlineGoogle Scholar28 Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Eng J Med. 2001; 344: 1895–1903.CrossrefMedlineGoogle Scholar29 Tam SH, Sassoli PM, Jordan RE, et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and αvβ3 integrins. Circulation. 1998; 98: 1085–1091.CrossrefMedlineGoogle Scholar30 Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997; 17: 528–535.CrossrefMedlineGoogle Scholar31 Kereiakes DJ, Lincoff AM, Anderson KM, et al. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol. 2002; 90: 628–630.CrossrefMedlineGoogle Scholar32 Bhatt D, Marso S, Lincoff A, et al. Abciximab reduces mortality in diabetics following percutaneous intervention. J Am Coll Cardiol. 2000; 35: 922–928.CrossrefMedlineGoogle Scholar33 Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation. 2001; 104: 2767–2771.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Cao B, Zhu L, Wang X, Zou R and Lu Z (2019) MicroRNA-365 promotes the contractile phenotype of venous smooth muscle cells and inhibits neointimal formation in rat vein grafts, IUBMB Life, 10.1002/iub.2022, 71:7, (908-916), Online publication date: 1-Jul-2019. Majithia A and Bhatt D (2018) Antiplatelet Therapy in Diabetes, Endocrinology and Metabolism Clinics of North America, 10.1016/j.ecl.2017.10.009, 47:1, (223-235), Online publication date: 1-Mar-2018. Akbarinia A, Kargarfard M and Naderi M (2018) Aerobic training improves platelet function in type 2 diabetic patients: role of microRNA-130a and GPIIb, Acta Diabetologica, 10.1007/s00592-018-1167-2, 55:9, (893-899), Online publication date: 1-Sep-2018. Ju L, McFadyen J, Al-Daher S, Alwis I, Chen Y, Tønnesen L, Maiocchi S, Coulter B, Calkin A, Felner E, Cohen N, Yuan Y, Schoenwaelder S, Cooper M, Zhu C and Jackson S (2018) Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets, Nature Communications, 10.1038/s41467-018-03430-6, 9:1, Online publication date: 1-Dec-2018. Graham B, Darabos C, Huang M, Muglia L, Moore J and Williams S (2017) Evolutionarily derived networks to inform disease pathways, Genetic Epidemiology, 10.1002/gepi.22078, 41:8, (866-875), Online publication date: 1-Dec-2017. Raja S (2016) Multivessel Disease in the PCI Era: Where Is CABG? Coronary Graft Failure, 10.1007/978-3-319-26515-5_1, (3-9), . Nwose E (2015) Cardiovascular Risk Assessment in Pre-Diabetes Glucose Intake and Utilization in Pre-Diabetes and Diabetes, 10.1016/B978-0-12-800093-9.00009-0, (103-117), . Iwasaki M, Otake H, Shinke T, Nakagawa M, Hariki H, Osue T, Inoue T, Taniguchi Y, Nishio R, Kinutani H, Konishi A, Hiranuma N, Kuroda M, Shite J and Hirata K (2014) Vascular Responses in Patients With and Without Diabetes Mellitus After Everolimus-Eluting Stent Implantation, Circulation Journal, 10.1253/circj.CJ-13-1540, 78:9, (2188-2196), . Soran O (2012) Percutaneous Versus Surgical Interventions for Coronary Artery Disease in Those with Diabetes Mellitus, Current Cardiology Reports, 10.1007/s11886-012-0323-5, 15:1, Online publication date: 1-Jan-2013. McDonald R, White K, Wu J, Cooley B, Robertson K, Halliday C, McClure J, Francis S, Lu R, Kennedy S, George S, Wan S, van Rooij E and Baker A (2013) miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation, European Heart Journal, 10.1093/eurheartj/eht105, 34:22, (1636-1643), Online publication date: 7-Jun-2013., Online publication date: 7-Jun-2013. Yeung J, Apopa P, Vesci J, Stolla M, Rai G, Simeonov A, Jadhav A, Fernandez-Perez P, Maloney D, Boutaud O, Holman T and Holinstat M (2017) 12-lipoxygenase activity plays an important role in PAR4 and GPVI-mediated platelet reactivity, Thrombosis and Haemostasis, 10.1160/TH13-01-0014, 110:09, (569-581), . Yin T, Wang G, Zhang D, Du D, Li Z, Luo L, Hou Y, Wang Y and Zhao J (2012) Endothelialization and in-stent restenosis on the surface of glycoprotein IIIa monoclonal antibody eluting stent, Journal of Biomedical Materials Research Part A, 10.1002/jbm.a.34078, 100A:6, (1398-1406), Online publication date: 1-Jun-2012. Jackson S (2011) Arterial thrombosis—insidious, unpredictable and deadly, Nature Medicine, 10.1038/nm.2515, 17:11, (1423-1436), Online publication date: 1-Nov-2011. Esposito G, Dellegrottaglie S and Chiariello M (2010) The extent of irreversible myocardial damage and the potential for left ventricular repair after primary percutaneous coronary intervention, American Heart Journal, 10.1016/j.ahj.2010.10.009, 160:6, (S4-S10), Online publication date: 1-Dec-2010. Beinart R, Abu Sham'a R, Segev A, Hod H, Guetta V, Shechter M, Boyko V, Behar S and Matetzky S (2010) The incidence and clinical predictors of early stent thrombosis in patients with acute coronary syndrome, American Heart Journal, 10.1016/j.ahj.2009.09.020, 159:1, (118-124), Online publication date: 1-Jan-2010. Garg S and Serruys P (2014) Benefits of and safety concerns associated with drug-eluting coronary stents, Expert Review of Cardiovascular Therapy, 10.1586/erc.09.138, 8:3, (449-470), Online publication date: 1-Mar-2010. Kim K (2010) PCI vs CABG in Complicated Diabetic Patients, Circulation Journal, 10.1253/circj.CJ-10-0131, 74:4, (622-623), . Arora R and Rai F (2009) Antiplatelet Intervention in Acute Coronary Syndrome, American Journal of Therapeutics, 10.1097/MJT.0b013e31804c7238, 16:5, (e29-e40), Online publication date: 1-Sep-2009. de la Hera J, Delgado E, Hernandez E, Garcia-Ruiz J, Vegas J, Avanzas P, Lozano I, Barriales-Villa R, Hevia S, Martin J, Alvarez F and Moris C (2009) Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention, European Heart Journal, 10.1093/eurheartj/ehp278, 30:21, (2614-2621), Online publication date: 1-Nov-2009. RAZMARA M, HJEMDAHL P, ÖSTENSON C and LI N (2008) Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: attenuation by glycoprotein IIb/IIIa inhibition, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2008.03185.x, 6:12, (2186-2192), Online publication date: 1-Dec-2008. Meliga E, Garcia-Garcia H, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree A, Gonzalo N, Cook S, Cruz-Gonzalez I, Marra S, De Servi S, Palacios I, Windecker S, van Domburg R, Colombo A, Sheiban I and Serruys P (2008) Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The Diabetes and Drug Eluting stent for LeFT main registry (D-DELFT), EuroIntervention, 10.4244/EIJV4I1A14, 4:1, (77-83), Online publication date: 1-May-2008. De Luca L, Sardella G, De Persio G, Petrolini A and Fedele F (2009) Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study, Acute Cardiac Care, 10.1080/17482940701747063, 10:2, (93-99), Online publication date: 1-Jan-2008. Wang G, Yin T, Luo L, Hou Y, Wang Y, Ruan C, Guzman R and Guidoin R (2012) Eluting characteristics of a platelet glycoprotein receptor antibody using a PLLA-coated stent, Journal of Biomaterials Science, Polymer Edition, 10.1163/156856208783721001, 19:3, (359-371), Online publication date: 1-Jan-2008. LIU Y, WANG L, YANG X, GE Y, WANG H, XU L, LI W, NI Z, XIA K, CHI Y, LI Q, ZHANG D, WU X, SUN H and GUO Z (2008) Gender differences in efficacy of primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction, Chinese Medical Journal, 10.1097/00029330-200812010-00002, 121:23, (2374-2378), Online publication date: 1-Dec-2008. Kini A, Kim M, Moreno P, Krishnan P, Ivan O and Sharma S (2008) Comparison of Coronary Flow Reserve and Fractional Flow Reserve in Patients With Versus Without Diabetes Mellitus and Having Elective Percutaneous Coronary Intervention and Abciximab Therapy (from the PREDICT Trial), The American Journal of Cardiology, 10.1016/j.amjcard.2007.10.053, 101:6, (796-800), Online publication date: 1-Mar-2008. Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P and Zoccai G (2008) Comparison of Effectiveness and Safety of Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With Diabetes Mellitus (from the Italian Multicenter Randomized DESSERT Study), The American Journal of Cardiology, 10.1016/j.amjcard.2008.01.040, 101:11, (1560-1566), Online publication date: 1-Jun-2008. Daemen J, Kuck K, Macaya C, LeGrand V, Vrolix M, Carrie D, Sheiban I, Suttorp M, Vranckx P, Rademaker T, Goedhart D, Schuijer M, Wittebols K, Macours N, Stoll H and Serruys P (2008) Multivessel Coronary Revascularization in Patients With and Without Diabetes Mellitus, Journal of the American College of Cardiology, 10.1016/j.jacc.2008.09.010, 52:24, (1957-1967), Online publication date: 1-Dec-2008. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg R, Hess O, Boersma E, Meier B, Windecker S and Serruys P (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study, The Lancet, 10.1016/S0140-6736(07)60314-6, 369:9562, (667-678), Online publication date: 1-Feb-2007. Williams M (2006) Coronary Revascularization in Diabetic Chronic Kidney Disease/End-Stage Renal Disease: A Nephrologist's Perspective, Clinical Journal of the American Society of Nephrology, 10.2215/CJN.00510705, 1:2, (209-220), Online publication date: 1-Mar-2006. Applegate R, Upadhya B, Little W, Xenakis M, Gandhi S, Baki T, Kahl F and Kutcher M (2006) Late outcomes after intervention of vein grafts in diabetics with abciximab use, International Journal of Cardiology, 10.1016/j.ijcard.2005.08.010, 111:1, (136-141), Online publication date: 1-Jul-2006. Daemen J and Serruys P (2006) Optimal revascularization strategies for multivessel coronary artery disease, Current Opinion in Cardiology, 10.1097/01.hco.0000245738.40088.70, 21:6, (595-601), Online publication date: 1-Nov-2006. Nolan P and Trujillo T (2005) Complications of the Medications Complications of Percutaneous Coronary Interventions, 10.1007/978-0-387-29301-1_2, (6-16), . Cosson E, Attali J and Valensi P (2005) Markers for silent myocardial ischemia in diabetes. Are they helpful?, Diabetes & Metabolism, 10.1016/S1262-3636(07)70187-8, 31:2, (205-213), Online publication date: 1-Apr-2005. Gurm H, Sarembock I, Kereiakes D, Young J, Harrington R, Kleiman N, Feit F, Wolski K, Bittl J, Wilcox R, Topol E and Lincoff A (2005) Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus, Journal of the American College of Cardiology, 10.1016/j.jacc.2005.02.074, 45:12, (1932-1938), Online publication date: 1-Jun-2005. Heeschen C and Hamm C Diabetiker und akutes Koronarsyndrom Diabetes und Herz, 10.1007/3-7985-1531-X_15, (255-271) Ong A, Aoki J, van Mieghem C, Rodriguez Granillo G, Valgimigli M, Tsuchida K, Sonnenschein K, Regar E, van der Giessen W, de Jaegere P, Sianos G, McFadden E, de Feyter P, van Domburg R and Serruys P (2005) Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents in 293 Consecutive Patients With Diabetes Mellitus (from the RESEARCH and T-SEARCH Registries), The American Journal of Cardiology, 10.1016/j.amjcard.2005.03.075, 96:3, (358-362), Online publication date: 1-Aug-2005. De Luca L, De Persio G, Minati M, Iacoboni C and Fedele F (2005) Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting, American Heart Journal, 10.1016/j.ahj.2005.02.015, 149:6, (1135.e11-1135.e18), Online publication date: 1-Jun-2005. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger P and Schömig A (2004) Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel, Circulation, 110:24, (3627-3635), Online publication date: 14-Dec-2004.Tang W and Lincoff A (2004) Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Blockade, Circulation, 110:24, (3618-3620), Online publication date: 14-Dec-2004. Zimarino M and De Caterina R (2004) Glycoprotein IIb-IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Interventions: from Pharmacology to Individual Patient's Therapy, Journal of Cardiovascular Pharmacology, 10.1097/00005344-200403000-00001, 43:3, (325-332), Online publication date: 1-Mar-2004. Casserly I and Moliterno D (2004) Diabetes and coronary revascularization: defining optimal revascularization modality and adjunctive medical treatment, ACC Current Journal Review, 10.1016/j.accreview.2004.04.096, 13:5, (71-76), Online publication date: 1-May-2004. Carter A (2004) TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent?, Catheterization and Cardiovascular Interventions, 10.1002/ccd.10764, 61:2, (233-236), Online publication date: 1-Feb-2004. Wilson Tang W, Maroo A and Young J (2004) Ischemic heart disease and congestive heart failure in diabetic patients, Medical Clinics of North America, 10.1016/j.mcna.2004.04.008, 88:4, (1037-1061), Online publication date: 1-Jul-2004. Exaire J and Lincoff A (2004) Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2004.00559.x, 2:1, (7-9), Online publication date: 1-Jan-2004. Jackson S and Schoenwaelder S (2003) Antiplatelet therapy: in search of the 'magic bullet', Nature Reviews Drug Discovery, 10.1038/nrd1198, 2:10, (775-789), Online publication date: 1-Oct-2003. Wu Y, Shi Y, Wu H, Bian C, Tang Q, Xu G, Yang J and Federici M (2011) Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis, PLoS ONE, 10.1371/journal.pone.0020759, 6:6, (e20759) March 25, 2003Vol 107, Issue 11 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000055653.52489.E9PMID: 12654616 Originally publishedMarch 25, 2003 PDF download Advertisement
Referência(s)